OMEROS CORP Amortization of Debt Issuance Costs
OMEROS CORP (OMER) reported Amortization of Debt Issuance Costs of $18.00 thousand for the 3-month period ending 2012-09-30, per its 10-Q filed 2012-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2012-11-09
- OMEROS CORP amortization of debt issuance costs for the quarter ending 2012-09-30 was $18.00K, a 5.26% decline year-over-year.
- OMEROS CORP amortization of debt issuance costs for the quarter ending 2012-06-30 was $19.00K, a 0.00% change year-over-year.
- OMEROS CORP amortization of debt issuance costs for the quarter ending 2011-09-30 was $19.00K.
- OMEROS CORP amortization of debt issuance costs for the quarter ending 2011-06-30 was $19.00K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month |
|---|---|---|---|
| 2012-09-30 | $18.00K 10-Q · filed 2012-11-09 | $37.00K derived: sum of 2 quarters · filed 2012-11-09 | $57.00K 10-Q · filed 2012-11-09 |
| 2012-06-30 | $19.00K 10-Q · filed 2012-08-07 | $39.00K 10-Q · filed 2012-08-07 | |
| 2011-09-30 | $19.00K 10-Q · filed 2012-11-09 | $38.00K derived: sum of 2 quarters · filed 2012-11-09 | $52.00K 10-Q · filed 2012-11-09 |
| 2011-06-30 | $19.00K 10-Q · filed 2012-08-07 | $33.00K 10-Q · filed 2012-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |